Efficacy of Tiotropium in COPD Patients with FEV1 ≥ 60% Participating in the UPLIFT® Trial

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/Guidelineitem.asp?l1 = 2&l2 = 1&intId = 2003. Updated 2009.
   Google Scholar
• Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; on behalf of the UPLIFT® study investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171–1178.
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease; analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10:59.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med 2007; 147:639–653.
   PubMed Web of Science ®Google Scholar
• Enright P. Don't prescribe tiotropium for smokers with an FEV1 above 60% predicted. Prim Care Respir J 2009; 18:119–120.
   PubMedGoogle Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A four-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543–1554.
   PubMed Web of Science ®Google Scholar
• McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, Niewoehner DE. Cause-specific mortality adjudication in the UPLFIT COPD trial: Findings and recommendations. Respir Med 2011 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2009; 103:963–974.
   Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.
   PubMed Web of Science ®Google Scholar
• Johansson G, Lindberg A, Romber K, Nordström L, Gerken F, Roquet A. Bronchodilator effiacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008; 17:169–175.
   PubMedGoogle Scholar
• Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145(2 Pt 1):467–470.
   PubMed Web of Science ®Google Scholar
• Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995(May Supplement); 107:187s–193s.
   Google Scholar
• Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56:880–887.
   PubMed Web of Science ®Google Scholar
• Jones PW, Brusselle GDal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler-Cataluña JJ, van der Molen T, Adamek L, Banik N. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 2011; 105:57–66.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:770–777.
   PubMed Web of Science ®Google Scholar
• Cooper CB. Airflow obstruction and exercise. Respir Med 2009; 103:325–334.
   PubMed Web of Science ®Google Scholar
• Babb TG, Viggiano R, Hurley B, Staats B, Rodarte JR. Effect of mild-to-moderate airflow limitation on exercise capacity. J Appl Physiol 1991; 70:223–230.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832–840.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86–94.
   PubMed Web of Science ®Google Scholar
• Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D. Improvements in symptom-limited exercise performance overy 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128:1168–78.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128–1138.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable COPD. Chest 2009; 136:1029–1038.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2007; 20:495–502.
   PubMed Web of Science ®Google Scholar
• Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparisons meta-analysis. Pharmacotherapy 2009: 29:891–905.
   PubMed Web of Science ®Google Scholar